Analysts Positive On Keryx Biopharmaceuticals, Inc. Despite Weak Prescription Data
May 05, 2015 at 12:24 PM EDT
Keryx posted total revenue of $1.175 million, including 1,218 prescriptions filled for Auryxia in the quarter.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|